Ranibizumab w leczeniu wysiękowego AMD – kilkuletnie obserwacje własne pacjentów z zachowaną dobrą ostrością wzroku mimo obecności rozległej błony neowaskularyzacji podsiatkówkowej
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2015
Słowa kluczowe:
ranizumab, zwyrodnienie plamki związane z wiekiem, rokowanie
##plugins.themes.bootstrap3.article.main##
Abstrakt
W codziennej praktyce klinicznej wyniki leczenia zwyrodnienia plamki związanego z wiekiem w wieloletniej obserwacji – szczególnie u pacjentów z czynnikami ryzyka utraty widzenia, takimi jak duża powierzchnia błony neowaskularyzacji podsiatkówkowej – mogą się różnić od wyników uzyskanych w badaniach klinicznych. W artykule przedstawiono 3 przypadki pacjentów, u których wieloletnia terapia ranibizumabem mimo obecności dużej błony neowaskularyzacji pozwoliła zachować dobrą ostrość wzroku. Omówiono przyczyny mogące wpływać na rokowanie u pacjentów z wysiękową postacią zwyrodnienia plamki związanego z wiekiem leczonych ranibizumabem przez wiele lat.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Śwituła M. Ranibizumab w leczeniu wysiękowego AMD – kilkuletnie obserwacje własne pacjentów z zachowaną dobrą ostrością wzroku mimo obecności rozległej błony neowaskularyzacji podsiatkówkowej. Ophthatherapy [Internet]. 31 marzec 2015 [cytowane 22 listopad 2024];2(1):48-5. Dostępne na: https://journalsmededu.pl/index.php/ophthatherapy/article/view/616
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Bressler N. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004; 291(15): 1900-1.
2. Kaiser P, Blodi B, Shapiro H et al; MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007; 114(10): 1868-75.
3. Brown D, Kaiser P, Michels M et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14): 1432-44.
4. Fung A, Lalwani G, Rosenfeld P et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007; 143(4): 566-83.
5. Lalwani G, Rosenfeld P, Fung A et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Am J Ophthalmol. 2009; 148(1): 43-58.
6. Martin D, Maguire M, Fine S et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012; 119(7): 1388-98.
7. Singer M, Awh C, Sadda S et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012; 119(6): 1175-83.
8. Rofagha S, Bhisitkul R, Boyer D et al. SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013; 120(11): 2292-9.
9. Rasmussen A, Bloch S, Fuchs J et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2013; 120(12): 2630-36.
10. Coco R, Sanabria M, Castrejon M et al. Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain. BMC Ophthalmol. 2014; 14: 138.
11. Ying G, Huang J, Maguire M et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013; 120(1): 122-9.
12. Korb C, Zwiener I, Lorenz K et al. Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration – evaluation in a clinical setting. BMC Ophthalmol. 2013; 13: 84.
13. Holz F, Bandello F, Gillies M et al. LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol. 2013; 97(9): 1161-7.
14. Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol. 2014; 252(4): 647-55.
15. Krüger Falk M, Kemp H, Sørensen T. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol. 2013; 155(1): 89-95.
16. Barthelmes D, Walton R, Campain A et al; for the Fight Retinal Blindness! Project Investigators. Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. Br J Ophthalmol. 2014 Sep 23. pii: bjophthalmol-2014-305514.
17. Ying G, Kim B, Maguire M et al. CATT Research Group. Sustained visual acuity loss in the comparison of age related macular degeneration treatments trials. JAMA Ophthalmol. 2014; 132(8): 915-21.
18. Daniel E, Toth C, Grunwald J et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014; 121(3): 656-66.
19. Grunwald J, Daniel E, Huang J et al; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014; 121(1): 150-61.
20. Bhisitkul R, Mendes T, Rofagha S et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA and HORIZON studies (SEVEN-UP Study). Am J Ophthalmol. 2015 Jan 29. pii: S0002 9394(15)00061-6.
2. Kaiser P, Blodi B, Shapiro H et al; MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007; 114(10): 1868-75.
3. Brown D, Kaiser P, Michels M et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14): 1432-44.
4. Fung A, Lalwani G, Rosenfeld P et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007; 143(4): 566-83.
5. Lalwani G, Rosenfeld P, Fung A et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Am J Ophthalmol. 2009; 148(1): 43-58.
6. Martin D, Maguire M, Fine S et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012; 119(7): 1388-98.
7. Singer M, Awh C, Sadda S et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012; 119(6): 1175-83.
8. Rofagha S, Bhisitkul R, Boyer D et al. SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013; 120(11): 2292-9.
9. Rasmussen A, Bloch S, Fuchs J et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2013; 120(12): 2630-36.
10. Coco R, Sanabria M, Castrejon M et al. Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain. BMC Ophthalmol. 2014; 14: 138.
11. Ying G, Huang J, Maguire M et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013; 120(1): 122-9.
12. Korb C, Zwiener I, Lorenz K et al. Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration – evaluation in a clinical setting. BMC Ophthalmol. 2013; 13: 84.
13. Holz F, Bandello F, Gillies M et al. LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol. 2013; 97(9): 1161-7.
14. Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol. 2014; 252(4): 647-55.
15. Krüger Falk M, Kemp H, Sørensen T. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol. 2013; 155(1): 89-95.
16. Barthelmes D, Walton R, Campain A et al; for the Fight Retinal Blindness! Project Investigators. Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. Br J Ophthalmol. 2014 Sep 23. pii: bjophthalmol-2014-305514.
17. Ying G, Kim B, Maguire M et al. CATT Research Group. Sustained visual acuity loss in the comparison of age related macular degeneration treatments trials. JAMA Ophthalmol. 2014; 132(8): 915-21.
18. Daniel E, Toth C, Grunwald J et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014; 121(3): 656-66.
19. Grunwald J, Daniel E, Huang J et al; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014; 121(1): 150-61.
20. Bhisitkul R, Mendes T, Rofagha S et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA and HORIZON studies (SEVEN-UP Study). Am J Ophthalmol. 2015 Jan 29. pii: S0002 9394(15)00061-6.